Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Hyperglucagonemia following oral glucose ingestion in patients with type 1 diabetes (and type 2 diabetes) has been claimed to result from impaired intraislet insulin inhibition of glucagon. We looked at plasma glucagon responses to the oral glucose tolerance test (OGTT) and isoglycemic intravenous glucose infusion (IIGI) in patients with type 1 diabetes. Nine patients without residual β-cell function [age: 25 ± 9 yr; body mass index (BMI): 24 ± 2 kg/m 2; fasting plasma glucose (FPG): 9.5 ± 2.1 mM; Hb A 1c: 8.4 ± 1.2% (mean ± SD)] and eight healthy subjects (age: 28 ± 5 yr; BMI: 24 ± 3 kg/m 2; FPG: 5.3 ± 0.2 mM; Hb A 1c: 5.0 ± 0.1%) were examined on two separate occasions: 4-h 50-g OGTT and IIGI. Isoglycemia during IIGIs was obtained using 53 ± 5 g of glucose in patients with type 1 diabetes and 30 ± 3 g in control subjects ( P < 0.001), resulting in gastrointestinal-mediated glucose disposal [100% × (glucose OGTT − glucose IIGI/glucose OGTT)] of −6 ± 9 and 40 ± 6% ( P < 0.01), respectively. Equal glucagon suppression during the two glucose stimuli was observed in healthy subjects, whereas patients with type 1 diabetes exhibited less inhibition in response to OGTT compared with IIGI (AUC: 1,519 ± 129 vs. 1,240 ± 86 pM·4 h; P = 0.03). This difference was even more pronounced during the initial 40 min with paradoxical hypersecretion of glucagon during OGTT and suppression during IIGI (AUC: 37 ± 13 vs. −33 ± 16 pM·40 min; P = 0.02). These results suggest that the inappropriate glucagon response to glucose in patients with type 1 diabetes occurs as a consequence of the oral administration way, suggesting a role of the gastrointestinal tract, possibly via glucagonotropic signaling from gut hormones (e.g., glucose-dependent insulinotropic polypeptide), in type 1 diabetic hyperglucagonemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 3×
“1 and Table 2), reflecting an intact incretin effect of 45 4% (19, 21).”
BackgroundMethodNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“GLP-1 has been shown to inhibit glucagon secretion (14, 22), whereas GIP has been shown to enhance glucagon secretion (16, 20) very much like GLP-2 (17, 27, 29).”
BackgroundSelf-citationNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 2×
“1 and Table 2), reflecting an intact incretin effect of 45 4% (19, 21).”
BackgroundMethodMuscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409 · cited 1×
“However, in patients with type 2 diabetes, we and others have recently observed a preserved suppression of glucagon secretion in response to intravenous glucose infused to copy the plasma glucose (PG) curve from a preceding oral glucose tolerance test (OGTT), which, as expected, caused inappropriate glucagon suppressi…”
BackgroundSelf-citationGlucagon physiology and pathophysiology in the light of new advances
Unger, R. H. (1985) · Diabetologia · doi:10.1007/bf00281991 · Cited by 361
Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314
Self-citationRaju, B., & Cryer, P. E. (2005) · Diabetes · doi:10.2337/diabetes.54.3.757 · Cited by 155 · cited 2×
“Lack of suppressive effect of hyperglycemia and reduced or lack of intraislet insulin have been suggested to play important roles in the inappropriately elevated plasma glucagon levels of diabetic patients (2, 3, 8, 25, 26, 28, 31).”
Background
Cited by
Ramzy, A., Thompson, D. M., Ward-Hartstonge, K. A., Ivison, S., Cook, L., Garcia, R. V., Loyal, J., Kim, P. T. W., Warnock, G. L., Levings, M. K., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.10.003 · Cited by 342
Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
Holst, J. J., Knop, F. K., Vilsbøll, T., Krarup, T., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-s227 · Cited by 280
Self-citationThe incretin system in healthy humans: The role of GIP and GLP-1
Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248
Self-citationMaddaloni, E., Bolli, G. B., Frier, B. M., Little, R. R., Leslie, R. D., Pozzilli, P., & Buzzetti, R. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14785 · Cited by 135
“cells may be unable to exert an efficient paracrine action to halt the inappropriate glucagon secretion in response to meals observed in people with type 1 diabetes.(48,49) A recent, large study of more than”
BackgroundSmits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
“The physiological importance of GLP-1 as an incretin hormone and a mediator of GIGD has been shown by studies in which its actions were blocked by the GLP-1 receptor blocker exendin(9-39).”
BackgroundInfluential
Metadata
- Authors
- Hare, K. J., Vilsbøll, T., Holst, J. J., & Knop, F. K.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2010-04
- Volume
- 298
- Issue
- 4
- Pages
- E832-E837
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2135741828
- Cited by
- 84
- References
- 8
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. https://app.cochat.ai/papers/10.1152/ajpendo.00700.2009
- The paper
- Hare, K. J., Vilsbøll, T., Holst, J. J., & Knop, F. K. (2010). Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. American Journal of Physiology-Endocrinology and Metabolism. https://doi.org/10.1152/ajpendo.00700.2009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.